Heron Therapeutics | HRTX - Ebit


Heron Therapeutics reported $-4.46M in EBIT for its fiscal quarter ending in September of 2024.





Ebit Change Date
ALKERMES USD -10.95M 100.03M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amarin USD -1.7M 8.47M Sep/2025
ANI Pharmaceuticals USD 29.13M 6.3M Dec/2025
Anika Therapeutics USD -4.28M 3.58M Mar/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
Eisai JPY 20.03B 6.36B Dec/2025
Esperion Therapeutics USD -16.03M 11.51M Sep/2024
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Heron Therapeutics USD -4.46M 5.76M Sep/2024
Insmed USD -249.71M 11.64M Dec/2025
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Nektar Therapeutics USD -34.34M 3.68M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Omeros USD -48.15M 7.25M Sep/2023
Pacira USD 3.19M 9.96M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Surmodics USD -322K 2.13M Dec/2023
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Veracyte USD 24.63M 1.52M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025